Strategies for successful management of moderate and severe Mooren's ulcer at a rural center during the COVID-19 pandemic: Lessons learnt.

Indian J Ophthalmol

Allen Foster Community Eye Health Research Centre, Gullapalli Pratibha Rao International Centre for Advancement of Rural Eye Care, LV Prasad Eye Institute, Hyderabad, Telangana, India.

Published: February 2024

Purpose: This study aimed to report the strategies that evolved in managing Mooren's ulcer (MU) at a resource-limited center in rural India during the coronavirus disease 2019 (COVID-19) pandemic.

Methods: This study includes a retrospective analysis of clinically diagnosed MU cases from January 2021 to August 2021 wherein strategies for management were developed. The demographic profile, ulcer clinical features, treatment algorithms (medical and surgical), complications encountered, referral to a higher center, and compliance with medication and follow-up were studied.

Results: The mean age of presentation was 68.1 years (range, 62-73 years), and 90% were men. The median best-corrected visual acuity (BCVA) was 1.26 logarithm of the Minimum Angle of Resolution (LogMAR) (interquartile range (IQR), 0.00-5 logMAR) in the affected eye on presentation, which improved to 0.69 logMAR (IQR, 0.00-3 logMAR) at resolution ( P = 0.442). The first-line management was conjunctival resection and tissue adhesive application (90%). 70% of cases were unilateral, 50% of cases had less than 2 clock hours of involvement, and 50% had less than 50% stromal involvement. Confounding factors included infectious keratitis (2) and corneal perforation (3). The mean duration of follow-up was 96 (1-240) days. The average follow-up visits per patient were 8.8 (1-22). 90% of cases could be managed successfully at the secondary center level with two cases needing a tertiary care referral.

Conclusion: MU can be managed effectively by following a systemic strategy of early diagnosis, surgical therapy, and rapid institution of systemic immunosuppression in a remote location-based secondary center. The strategies developed can be a guide for ophthalmologists at remote centers managing patients or who are unable to travel to tertiary institutes.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10941921PMC
http://dx.doi.org/10.4103/IJO.IJO_1057_23DOI Listing

Publication Analysis

Top Keywords

mooren's ulcer
8
secondary center
8
center
5
cases
5
strategies
4
strategies successful
4
successful management
4
management moderate
4
moderate severe
4
severe mooren's
4

Similar Publications

Risk factors for recurrence of Mooren's ulcer after keratoplasty.

Heliyon

November 2024

Xiamen Eye Center and Eye Institute of Xiamen University, School of Medicine, Xiamen, China.

Purpose: The purpose of this study was to investigate the clinical characteristics of patients with corneal Mooren's ulcers (MU) and explore potential risk factors for recurrence after keratoplasty.

Methods: The study retrospectively analyzed 87 patients (101 eyes) diagnosed with MU. Factors associated with recurrence after keratoplasty were identified using correlation analysis, and a clinical scoring system was developed based on the magnitude of the univariate and multivariate logistic regression analysis.

View Article and Find Full Text PDF

[Case report of a severe Mooren's ulcer].

Ann Pathol

October 2024

Service de pathologie, CHU de Reims, 51100 Reims, France; MEDyC UMR 7369, université de Reims Champagne-Ardenne, 51100 Reims, France.

Mooren's ulcer is a painless and idiopathic ulcer of the peripheral cornea related to autoimmunity against a corneal stromal antigen, calgranulin C. Corneal involvement is isolated. There are no specific histopathological features to differentiate Mooren's ulcer from pseudo-Mooren's, the latter being part of a systemic disease.

View Article and Find Full Text PDF
Article Synopsis
  • Mooren's ulcer (MU) is a rare and serious eye condition that causes crescent-shaped corneal ulcers, which can lead to blindness if untreated.
  • Despite various treatments available, there is no definitive evidence on the best approach due to a lack of thorough clinical trials.
  • A case study of a 20-year-old male who underwent a personalized treatment plan using corticosteroids, surgery, and Cyclosporine A showed successful healing of the ulcer and no disease recurrence, with AS-OCT imaging helping to guide the treatment effectively.
View Article and Find Full Text PDF

Objective: Miltefosine stands as the sole oral medication approved for the treatment of leishmaniasis. The appearance of severe ophthalmic toxicities induced by miltefosine in the context of leishmaniasis treatment is a matter of significant concern. The main objective of this study is to present a comprehensive summary of the ophthalmic adverse effects associated with miltefosine when used in the treatment of leishmaniasis.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!